Role of integrins in fibrosing liver diseases

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 301, Issue 3, 2011, Pages

  Patsenker, Eleonora ^a   Stickel, Felix ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antifibrotic therapy; Extracellular matrix; Hepatic stellate cell myofibroblast; Inflammation

Indexed keywords

ANTIFIBROTIC AGENT; ATORVASTATIN; CELL ADHESION MOLECULE; CYSTEINYLARGINYLSERYLASPARTYLTHREONYLLEUCYLCYSTEINAMIDE; CYSTEINYLARGINYLSERYLASPARTYLTHREONYLLEUCYLCYSTEINYLGLYCYLGLUTAMYLAMIDE; EMD 527040; GLYCYLARGINYLGLYCYLASPARTYLSERINE; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; ARTICLE; CHOLESTASIS; DISEASE COURSE; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; MOLECULAR EVOLUTION; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL;

CHOLESTASIS, INTRAHEPATIC; FATTY LIVER; FIBROSIS; HEPATIC STELLATE CELLS; HEPATITIS, VIRAL, HUMAN; HUMANS; INFLAMMATION; INTEGRINS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; SIGNAL TRANSDUCTION;

EID: 80052278538     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00050.2011     Document Type: Article

References (83)

1. Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L. Understanding and treating patients with alcoholic cirrhosis: an update. Alcohol Clin Exp Res 33: 1136-1144, 2009.
2. Aspinall AI, Curbishley SM, Lalor PF, Weston CJ, Liaskou E, Adams RM, Holt AP, Adams DH. CX(3)CR1 and vascular adhesion protein-1- dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. Hepatology 51: 2030-2039.
3. Banerjee A, Lee JH, Ramaiah SK. Interaction of osteopontin with neutrophil alpha(4)beta(1) and alpha(9)beta(1) integrins in a rodent model of alcoholic liver disease. Toxicol Appl Pharmacol 233: 238-246, 2008.
4. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115: 209-218, 2005.
5. Bautista AP. Chronic alcohol intoxication enhances the expression of CD18 adhesion molecules on rat neutrophils and release of a chemotactic factor by Kupffer cells. Alcohol Clin Exp Res 19: 285-290, 1995.
6. Bautista AP. Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein-2 production and intercellular adhesion molecule-1 expression in the liver. Hepatology 25: 335-342, 1997.
7. Bendeck MP, Irvin C, Reidy M, Smith L, Mulholland D, Horton M, Giachelli CM. Smooth muscle cell matrix metalloproteinase production is stimulated via alpha(v)beta(3) integrin. Arterioscler Thromb Vasc Biol 20: 1467-1472, 2000.
8. Bruck R, Hershkoviz R, Lider O, Shirin H, Aeed H, Halpern Z. Non-peptidic analogs of the cell adhesion motif RGD prevent experimental liver injury. Isr Med Assoc J 2 Suppl: 74-80, 2000.
9. Bruck R, Hershkoviz R, Lider O, Shirin H, Aeed H, Halpern Z. The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury. Yale J Biol Med 70: 391-402, 1997.
10. Burra P, Hubscher SG, Shaw J, Elias E, Adams DH. Is the intercellular adhesion molecule-1/leukocyte function associated antigen 1 pathway of leukocyte adhesion involved in the tissue damage of alcoholic hepatitis? Gut 33: 268-271, 1992.
11. Chedid A, Mendenhall CL, Moritz TE, French SW, Chen TS, Morgan TR. Expression of the beta 1 chain (CD29) of integrins and CD45 in alcoholic liver disease. The VA Cooperative Study Group No 275. Am J Gastroenterol 88: 1920-1927, 1993.
12. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 268: 233-239, 1995.
13. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev 14: 195-228, 1994.
14. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39: 1631-1638, 2004.
15. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
16. Dold S, Laschke MW, Lavasani S, Menger MD, Thorlacius H. Cholestatic liver damage is mediated by lymphocyte function antigen-1-dependent recruitment of leukocytes. Surgery 144: 385-393, 2008.
17. Dubree NJ, Artis DR, Castanedo G, Marsters J, Sutherlin D, Caris L, Clark K, Keating SM, Beresini MH, Chiu H, Fong S, Lowman HB, Skelton NJ, Jackson DY. Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents. J Med Chem 45: 3451-3457, 2002.
18. Friedman SL, Bansal MB. Reversal of hepatic fibrosis-fact or fantasy? Hepatology 43: S82-S88, 2006.
19. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 100: 4498-4503, 2003.
20. Giancotti FG, Ruoslahti E. Integrin signaling. Science 285: 1028-1032, 1999.
21. Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 19: 173-206, 2003.
22. Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 33: 1065-1072, 2001.
23. Gujral JS, Farhood A, Bajt ML, Jaeschke H. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology 38: 355-363, 2003.
24. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Levy P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344: 418-423, 2001.
25. Hemler ME. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 8: 365-400, 1990.
26. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams DH. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 174: 1055-1062, 2005.
27. Huang G, Brigstock DR. Integrin expression and function in the response of primary culture hepatic stellate cells to connective tissue growth factor (CCN2). J Cell Mol Med 15: 1087-1095, 2011.
28. Huang XW, Wang JY, Li F, Song ZJ, Xie C, Lu WY. Biochemical characterization of the binding of cyclic RGDyK to hepatic stellate cells. Biochem Pharmacol 80: 136-143.
29. Hynes RO. The emergence of integrins: a personal and historical perspective. Matrix Biol 23: 333-340, 2004.
30. Jackson C. Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens 11: 295-299, 2002.
31. Jafri M, Donnelly B, Allen S, Bondoc A, McNeal M, Rennert PD, Weinreb PH, Ward R, Tiao G. Cholangiocyte expression of α2β1- integrin confers susceptibility to rotavirus-induced experimental biliary atresia. Am J Physiol Gastrointest Liver Physiol 295: G16-G26, 2008.
32. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6: 587-595, 2009.
33. Kodali P, Wu P, Lahiji PA, Brown EJ, Maher JJ. ANIT toxicity toward mouse hepatocytes in vivo is mediated primarily by neutrophils via CD18. Am J Physiol Gastrointest Liver Physiol 291: G355-G363, 2006.
34. Kotoh K, Nakamuta M, Kohjima M, Fukushima M, Morizono S, Kobayashi N, Enjoji M, Nawata H. Arg-Gly-Asp (RGD) peptide ameliorates carbon tetrachloride-induced liver fibrosis via inhibition of collagen production and acceleration of collagenase activity. Int J Mol Med 14: 1049-1053, 2004.
35. Levine D, Rockey DC, Milner TA, Breuss JM, Fallon JT, Schnapp LM. Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis. Am J Pathol 156: 1927-1935, 2000.
36. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119: 172-180, 2000.
37. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 25: 619-647, 2007.
38. Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol 18: 579-586, 2006.
39. Milliano MT, Luxon BA. Initial signaling of the fibronectin receptor (alpha5beta1 integrin) in hepatic stellate cells is independent of tyrosine phosphorylation. J Hepatol 39: 32-37, 2003.
40. Milner R, Campbell IL. The integrin family of cell adhesion molecules has multiple functions within the CNS. J Neurosci Res 69: 286-291, 2002.
41. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 157: 493-507, 2002.
42. Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 48: 963-977, 2008.
43. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328, 1999.
44. Nadler EP, Patterson D, Violette S, Weinreb P, Lewis M, Magid MS, Greco MA. Integrin alphavbeta6 and mediators of extracellular matrix deposition are up-regulated in experimental biliary atresia. J Surg Res 154: 21-29, 2009.
45. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Lowdose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 45: 786-796, 2006.
46. Nejjari M, Couvelard A, Mosnier JF, Moreau A, Feldmann G, Degott C, Marcellin P, Scoazec JY. Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C. J Pathol 195: 473-481, 2001.
47. Panasiuk A, Zak J, Maciorkowska E, Panasiuk B, Prokopowicz D. Expression of beta2-integrin on leukocytes in liver cirrhosis. World J Gastroenterol 12: 6193-6197, 2006.
48. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 135: 660-670, 2008.
49. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, Niedobitek G, Goodman SL, Schuppan D. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 50: 1501-1511, 2009.
50. Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGFBB- induced hepatic stellate cell migration and activation in vitro. J Hepatol 46: 878-887, 2007.
51. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2010 Dec 17. [Epub ahead of print]
52. Ponsioen CY, Kuiper H, Ten Kate FJ, van Milligen de Wit M, van Deventer SJ, Tytgat GN. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 11: 769-774, 1999.
53. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A, Friess H, Schuppan D. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 48: 453-464, 2008.
54. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 50: 1294-1306, 2009.
55. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136: 1618-1628.e2, 2009.
56. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313, 2002.
57. Qin J, Vinogradova O, Plow EF. Integrin bidirectional signaling: a molecular view. PLoS Biol 2: e169, 2004.
58. Racine-Samson L, Rockey DC, Bissell DM. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 272: 30911-30917, 1997.
59. Ramaiah SK, Jaeschke H. Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury. Toxicol Mech Methods 17: 431-440, 2007.
60. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev 29: 223-237, 2010.
61. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 3: 95-107, 2005.
62. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12: 697-715, 1996.
63. Sacanella E, Estruch R, Gaya A, Ferrer K, Fernandez-Sola J, Alonso JR, Nicolas JM, Urbano-Marquez A. Upregulated expression of VLA proteins and CD29 in peripheral blood lymphocytes of chronic alcoholics without ethanol-related diseases. Alcohol Clin Exp Res 23: 371-375, 1999.
64. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 371: 838-851, 2008.
65. Schuppan D, Popov Y. Rationale and targets for antifibrotic therapies. Gastroenterol Clin Biol 33: 949-957, 2009.
66. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21: 351-372, 2001.
67. Shi C, Velazquez P, Hohl TM, Leiner I, Dustin ML, Pamer EG. Monocyte trafficking to hepatic sites of bacterial infection is chemokine independent and directed by focal intercellular adhesion molecule-1 expression. J Immunol 184: 6266-6274.
68. + T cells in primary biliary cirrhosis. Dig Dis Sci 47: 1209-1215, 2002.
69. Streuli CH. Integrins and cell-fate determination. J Cell Sci 122: 171-177, 2009.
70. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, Vogt A, Dienes HP, Lammert F, Reichen J, Heller J, Sauerbruch T. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53: 702-712.
71. Volpes R, van den Oord JJ, Desmet VJ. Distribution of the VLA family of integrins in normal and pathological human liver tissue. Gastroenterology 101: 200-206, 1991.
72. Wang B, Dolinski BM, Kikuchi N, Leone DR, Peters MG, Weinreb PH, Violette SM, Bissell DM. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 46: 1404-1412, 2007.
73. Yamauchi M, Mizuhara Y, Toda G. Serum vitronectin receptor in alcoholic liver disease: correlation with fibronectin receptor and morphological features. Alcohol Alcohol Suppl 1A: 37-43, 1993.
74. Yang CQ, Yang L, Yang WZ, Zhang Z, Zhang H, Chang YZ, Yuan M, Chen XM. [Mechanism of hepatic stellate cell migration during liver fibrosis]. Zhonghua Yi Xue Za Zhi 88: 119-122, 2008.
75. Yasoshima M, Nakanuma Y, Tsuneyama K, Van de Water J, Gershwin ME. Immunohistochemical analysis of adhesion molecules in the micro-environment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol 175: 319-325, 1995.
76. Yasoshima M, Tsuneyama K, Harada K, Sasaki M, Gershwin ME, Nakanuma Y. Immunohistochemical analysis of cell-matrix adhesion molecules and their ligands in the portal tracts of primary biliary cirrhosis. J Pathol 190: 93-99, 2000.
77. Zhang M, Han Y, Han C, Xu S, Bao Y, Chen Z, Gu Y, Xia D, Cao X. The beta2 integrin CD11b attenuates polyinosinic:polycytidylic acidinduced hepatitis by negatively regulating natural killer cell functions. Hepatology 50: 1606-1616, 2009.
78. Zhang Y, Ikegami T, Honda A, Miyazaki T, Bouscarel B, Rojkind M, Hyodo I, Matsuzaki Y. Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. Hepatology 44: 612-622, 2006.
79. Zhang ZX, Sonnerborg A, Sallberg M. A cell-binding Arg-Gly-Asp sequence is present in close proximity to the major linear antigenic region of HCV NS3. Biochem Biophys Res Commun 202: 1352-1356, 1994.
80. Zhou X, Jamil A, Nash A, Chan J, Trim N, Iredale JP, Benyon RC. Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: implications for regulation of liver fibrosis. J Biol Chem 281: 39757-39765, 2006.
81. Zhou X, Murphy FR, Gehdu N, Zhang J, Iredale JP, Benyon RC. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 279: 23996-24006, 2004.
82. Znoyko I, Trojanowska M, Reuben A. Collagen binding alpha2beta1 and alpha1beta1 integrins play contrasting roles in regulation of Ets-1 expression in human liver myofibroblasts. Mol Cell Biochem 282: 89-99, 2006.
83. Zong H, Bastie CC, Xu J, Fassler R, Campbell KP, Kurland IJ, Pessin JE. Insulin resistance in striated muscle-specific integrin receptor beta1- deficient mice. J Biol Chem 284: 4679-4688, 2009.